3681 Stock Overview
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics.
SinoMab BioScience Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$1.83|
|52 Week High||HK$3.19|
|52 Week Low||HK$0.83|
|1 Month Change||1.67%|
|3 Month Change||-1.08%|
|1 Year Change||-42.63%|
|3 Year Change||-54.82%|
|5 Year Change||n/a|
|Change since IPO||-69.50%|
Recent News & Updates
Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last YearMar 04
What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor CompositionJan 28
Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?Jan 01
Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-TermNov 30
|3681||HK Biotechs||HK Market|
Return vs Industry: 3681 exceeded the Hong Kong Biotechs industry which returned -52% over the past year.
Return vs Market: 3681 underperformed the Hong Kong Market which returned -24.6% over the past year.
|3681 Average Weekly Movement||5.0%|
|Biotechs Industry Average Movement||11.3%|
|Market Average Movement||8.0%|
|10% most volatile stocks in HK Market||15.0%|
|10% least volatile stocks in HK Market||3.9%|
Stable Share Price: 3681 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 3681's weekly volatility (5%) has been stable over the past year.
About the Company
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton’s tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, as well as in phase 1 clinical trial to treat multiple sclerosis, SLE, and NMOSD.
SinoMab BioScience Limited Fundamentals Summary
|3681 fundamental statistics|
Is 3681 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|3681 income statement (TTM)|
|Cost of Revenue||CN¥0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.31|
|Net Profit Margin||-1,191.36%|
How did 3681 perform over the long term?See historical performance and comparison